natgillin/translations-raw huggingface dataset:
The efficacy of Kalydeco has been evaluated in two Phase 3 randomised, double-blind, placebo-controlled, multi-centre studies of clinically stable patients with CF who had the G551D mutation in the CFTR gene on at least 1 allele and had FEV1 ≥40% predicted.
Učinkovitost zdravila Kalydeco so ovrednotili v dveh randomiziranih, dvojno slepih, s placebom kontroliranih multicentričnih študijah 3. faze, opravljenih na klinično stabilnih bolnikih s CF, ki so imeli mutacijo G551D na genu CFTR na vsaj 1 alelu in FEV1 ≥ 40 % napovedane.
The efficacy of Kalydeco in patients less than 18 years of age with an R117H mutation in the CFTR gene has not been established.
Učinkovitost zdravila Kalydeco pri bolnikih, mlajših od 18 let, z mutacijo R117H na genu CFTR ni bila dokazana.
The efficacy of Kineret in children with RA (JIA) aged 0 to 18 years has not been established.
Učinkovitost zdravila Kineret pri otrocih z RA (JIA), starih od 0 do 18 let, ni bila dokazana.
The efficacy of ledipasvir/sofosbuvir in patients who had previously failed treatment with sofosbuvir + ribavirin ± PEG-IFN is supported by two clinical studies.
Učinkovitost ledipasvirja/sofobuvirja pri bolnikih, pri katerih je bilo predhodno zdravljenje s sofobuvirjem + ribavirinom ± PEG-IFN neuspešno, so podprli z dvema kliničnima študijama.
The efficacy of leflunomide in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of leflunomide in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost leflunomida so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of leflunomide in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost zdravila Leflunomid Teva so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of Leflunomide medac in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost zdravila Leflunomid medac so pri zdravljenju revmatoidnega artritisa dokazali v kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of Leflunomide ratiopharm in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost zdravila Leflunomid ratiopharm so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of Leflunomide Winthrop in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost zdravila Leflunomid Winthrop so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II. fazi in 3 v III. fazi).
The efficacy of Leflunomide Winthrop was demonstrated in one controlled, randomised, double blind study 3L01 in 188 patients with psoriatic arthritis, treated at 20 mg/day.
Učinkovitost zdravila Leflunomid Winthrop je dokazala kontrolirana, randomizirana dvojno slepa študija 3L01 pri 188 bolnikih s psoriatičnim artritisom.
The efficacy of Livensa is reduced if your estrogen therapy is of a certain type (‘conjugated equine estrogens’).
Učinkovitost zdravila Livensa se zmanjša, če se zdravite z določeno vrsto estrogenov (‘konjugirani konjski estrogeni’).
The efficacy of lurasidone in the treatment of schizophrenia was demonstrated in five multi-centre, placebo-controlled, double-blind, 6-week trials in subjects who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia.
Učinkovitost lurasidona pri zdravljenju shizofrenije je bila dokazana v petih multicentričnih, s placebom nadzorovanih, dvojno slepih, 6-tedenskih preskušanjih pri osebah, ki so izpolnjevale kriterije za shizofrenijo po DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition).
The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials.
Ena infuzija 5 mg zoledronske kisline se je izkazala za bolj učinkovito kot odmerek 30 mg risedronata na dan v 2 mesecih v dveh 6–mesečnih primerjalnih preskusih.
The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials.
V dveh 6–mesečnih primerjalnih preskusih se je ena infuzija 5 mg zoledronske kisline izkazala za bolj učinkovito kot dvomesečna uporaba 30 mg risedronata na dan.
The efficacy of oseltamivir in either treatment or prophylaxis of influenza in immunocompromised patients has not been firmly established (see section 5.1).
Učinkovitost oseltamivirja pri zdravljenju ali pri preprečevanju gripe pri imunsko ogroženih bolnikih ni zanesljivo dokazana (glejte poglavje 5.1).
The efficacy of OSSEOR was demonstrated in men with osteoporosis in a 2-year, double-blind, placebo-controlled study with a main analysis after one year in 243 patients (Intention to treat population, 161 patients received strontium ranelate) at high risk of fracture (mean age 72,7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture).
Učinkovitost zdravila OSSEOR je bila pri moških z osteoporozo dokazana v dvojno slepi, s placebom nadzorovani študiji, ki je trajala 2 leti, z glavno analizo po enem letu pri 243 bolnikov (ITT – populacija bolnikov, ki so jih nameravali zdraviti, 161 bolnikov je prejemalo stroncijev ranelat) s povečanim tveganjem za zlome (srednja starost 72,7 let; vrednost T srednje mineralne kostne gostote v ledveni hrbtenici -2,6; obstoječi zlomi vretenc pri 28 %).
The efficacy of OZURDEX was assessed in two 3 year, multicentre, double-masked, randomised, sham-controlled, parallel studies of identical design which together comprised 1,048 patients (studies 206207-010 and 206207-011).
Učinkovitost zdravila OZURDEX so ocenili v dveh triletnih multicentričnih, dvojno slepih, randomiziranih, s placebom nadzorovanih vzporednih študijah z istim načrtom, ki sta vključili skupno 1048 bolnikov (študiji 206207-010 in 206207-011).
The efficacy of palivizumab when administered to patients as a second course of treatment during an ensuing RSV season has not been formally investigated in a study performed with this objective.
Učinkovitost palivizumaba pri bolnikih, ki ga dobijo v ponovnem ciklusu naslednjo sezono RSV, ni bila formalno preskušena v kakšni študiji, opravljeni s tem namenom.
The efficacy of pasireotide intramuscular use has been demonstrated in two phase III, multicentre studies.
Učinkovitost pasireotida za intramuskularno uporabo so dokazali v dveh multicentričnih študijah faze III.
The efficacy of perampanel in partial-onset seizures was established in three adjunctive therapy 19 week, randomised, double-blind, placebo-controlled, multicentre trials in adult and adolescent patients.
Učinkovitost perampanela pri napadih s parcialnim izvorom so ugotavljali v treh 19-tedenskih, randomiziranih, dvojno slepih, s placebom kontroliranih multicentričnih preskušanjih s pomožnim zdravljenjem pri odraslih bolnikih in mladostnikih.
The efficacy of Perjeta in HER2-positive breast cancer is supported by a randomised phase III comparative trial in metastatic breast cancer and two phase II studies (one single-arm trial in metastatic breast cancer and one randomised comparative trial in the neoadjuvant setting).
Učinkovitost zdravila Perjeta pri HER2 pozitivnem raku dojk potrjuje primerjalno randomizirano preskušanje faze III pri metastatskem raku dojk in dve študiji faze II (ena z enim samim krakom pri metastatskem raku dojk in ena randomizirana primerjalna v okviru neoadjuvantnega zdravljenja).
The efficacy of pramipexole was evaluated in four placebo-controlled clinical trials in approximately 1,000 patients with moderate to very severe idiopathic Restless Legs Syndrome.
Učinkovitost pramipeksola so ocenili v štirih s placebom nadzorovanih kliničnih preskušanjih pri približno 1.000 bolnikih z zmernim do zelo hudim idiopatskim sindromom nemirnih nog.
The efficacy of Prometax transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Učinkovitost transdermalnih obližev Prometax pri bolnikih z Alzheimerjevo demenco so dokazali v 24-tedenski dvojno slepi, s placebom kontrolirani osnovni študiji in njenem odprtem podaljšku ter v 48-tedenski dvojno slepi primerjalni študiji.
The efficacy of propranolol in infants (aged 5 weeks to 5 months at treatment initiation) with proliferating infantile haemangioma requiring systemic therapy has been demonstrated in a pivotal randomised, controlled, multicentre, multidose, adaptive phase II/III study aimed to compare four regimens of propranolol (1 or 3 mg/kg/day for 3 or 6 months) to placebo (double blind).
Učinkovitost propranolola pri dojenčkih (starosti od 5 tednov do 5 mesecev na začetku zdravljenja) z močno povečanim infantilnim hemangiomom, ki zahteva sistematično zdravljenje, je bila dokazana v osrednji randomizirani, nadzorovani, multicentrični študiji faze II/III z več odmerki z možnim prilagajanjem, katere cilj je bil primerjava štirih režimov propranolola (1 ali 3 mg/kg/dan 3 ali mesecev) in placeba (dvojno slepa).
The efficacy of PROTELOS was demonstrated in men with osteoporosis in a 2-year, double- blind,placebo-controlled study with a main analysis after one year in 243 patients (Intention to treatpopulation, 161 patients received strontium ranelate) at high risk of fracture (mean age 72,7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture).
Učinkovitost zdravila PROTELOS je bila pri moških z osteoporozo dokazana v dvojno slepi, s placebom nadzorovani študiji, ki je trajala 2 leti, z glavno analizo po enem letu pri 243 bolnikov (ITT – populacija bolnikov, ki so jih nameravali zdraviti, 161 bolnikov je prejemalo stroncijev ranelat) s povečanim tveganjem za zlome (srednja starost 72,7 let; vrednost T srednje mineralne kostne gostote v ledveni hrbtenici -2,6; obstoječi zlomi vretenc pri 28 %).
The efficacy of qHPV vaccine against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7% (95% CI: 67.5, 93.7).
Učinkovitost qHPV cepiva proti kombinirani pojavnosti s HPV 16 ali 18 povezane persistentne okužbe, genitalnih bradavic, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu je bila 84,7 % (95 % IZ: 67,5; 93,7).
The efficacy of qHPV vaccine in 24- through 45-year-old women was assessed in 1 placebo- controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women.
Učinkovitost qHPV cepiva pri ženskah, starih od 24 do 45 let, so ovrednotili v 1 dvojno slepi, randomizirani, s placebom nadzorovani klinični študiji III. faze (Protokol 019, FUTURE III), v katero je bilo vključenih 3.817 žensk.
The efficacy of Quadrisol was compared with another similar product.
Učinkovitost zdravila Quadrisol so primerjali z drugim podobnim zdravilom.
The efficacy of re-administration has not been established, for safety see section 4.4. Special populations
Učinkovitost ponovne uporabe ni bila ugotovljena.
The efficacy of repeated infusions with infliximab in patients with fistulising Crohn’s disease was studied in a 1-year clinical study (ACCENT II).
Učinkovitost večkratnih infuzij infliksimaba pri bolnikih s Crohnovo boleznijo s fistulami so raziskovali v enoletni klinični študiji (ACCENT II).
The efficacy of reslizumab in eosinophilic asthma (blood eosinophils ≥400 µL-1) was evaluated in three randomised, double-blind, placebo-controlled studies (Studies I to III) from 16 to 52 weeks’ duration involving 1268 patients with moderate to severe asthma inadequately controlled on medium- to high-dose inhaled corticosteroids (ICS) (at least 440 μg of fluticasone propionate daily or equivalent) with or without other controllers; prior stable allergen immunotherapy was allowed.
Učinkovitost reslizumaba pri eozinofilni astmi (eozinofilci v krvi ≥ 400 µl-1) so ocenili v treh randomiziranih, dvojno slepih, s placebom nadzorovanih študijah (študije I do III), ki so trajale od 16 do 52 tednov in vključevale 1.268 bolnikov z zmerno do hudo astmo, ki s srednje visokimi do visokimi odmerki inhaliranih kortikosteroidov (IKS) (vsaj 440 μg flutikazonpropionata ali ustreznega zdravila na dan) z drugimi zdravili za obvladovanje ali brez njih ni bila ustrezno urejena; predhodna stabilna imunoterapija na alergene je bila dovoljena.
The efficacy of Resolor was established in three multicentre, randomised, double-blind, 12-week placebo-controlled studies in subjects with chronic constipation (n=1,279 onResolor, 1,124 females, 155 males).
Učinkovitost zdravila Resolor je bila dokazana v treh multicentričnih randomiziranih, dvojno slepih dvanajsttedenskih s placebom nadzorovanih študijah pri osebah s kroničnim zaprtjem (n = 1.279 na zdravilu Resolor, 1.124 žensk, 155 moških).
The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatment- experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Učinkovitost zdravila REYATAZ/ritonavirja v kombinaciji z dizoproksiltenofovirat fumaratom pri predhodno že zdravljenih bolnikih je bila dokazana v klinični študiji 045, pri predhodno še nezdravljenih bolnikih pa v klinični študiji 138 (glejte poglavji 4.8 in 5.1).
The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo so dokazali v 24-tedenski multicentrični, dvojno slepi, s placebom nadzorovani osrednji študiji in naknadni 24-tedenski odprti študiji.
The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom nadzorovani osrednji študiji in naknadni 24-tedenski odprti fazi.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo, so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom kontrolirani osnovni študiji in njeni 24-tedenski odprti podaljšani fazi.
The efficacy of rivastigmine transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Učinkovitost transdermalnih obližev z rivastigminom pri bolnikih z Alzheimerjevo demenco so dokazali v 24-tedenski dvojno slepi, s placebom kontrolirani osnovni študiji in njenem odprtem podaljšku ter v 48-tedenski dvojno slepi primerjalni študiji.
The efficacy of rotigotine was evaluated in 5 placebo-controlled trials with more than 1,400 patients with idiopathic Restless Legs Syndrome (RLS).
Učinkovitost rotigotina so ocenili v petih s placebom kontroliranih študijah z več kot 1.400 bolniki z idiopatičnim sindromom nemirnih nog (Restless Legs Syndrome - RLS).
The efficacy of selexipag on the primary endpoint was consistent across subgroups of age, sex, race, aetiology, geographical region, WHO FC, and as monotherapy or in combination with an ERA or a PDE-5 inhibitor or triple combination with both an ERA and a PDE-5 inhibitor.
Učinkovitost seleksipaga na primarni opazovani dogodek je bil skladen v vseh podskupinah starosti, spola, ras, etiologije, zemljepisne regije, FK po SZO, in kot monoterapija ali v kombinaciji z ERA ali zaviralcem PDE-5 ali kot trojna kombinacija z ERA in zaviralcem PDE-5.
The efficacy of Selincro was also evaluated in a randomised, double-blind, parallel-group, placebo-controlled 1-year study.
Učinkovitost zdravila Selincro je bila prav tako ocenjena v randomizirani, dvojno slepi, z vzporednima skupinama in s placebom nadzorovani enoletni študiji.
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 41.6% (95% CI: 24.3, 55.2).
Učinkovitost cepiva Silgard proti kombinirani pojavnosti s HPV 16 ali HPV 18 povezane persistentne okužbe, bradavic na spolovilih, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu je bila 41,6 % (95-odstotni IZ: 24,3; 55,2).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7% (95% CI: 67.5, 93.7).
Učinkovitost cepiva Silgard proti kombinirani pojavnosti s HPV 16 ali HPV 18 povezane persistentne okužbe, bradavic na spolovilih, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu je bila 84,7 % (95-odstotni IZ: 67,5; 93,7)
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 47.2% (95% CI: 33.5, 58.2).
Učinkovitost cepiva Silgard proti kombinirani pojavnosti s HPV 6, HPV 11, HPV 16 ali HPV 18 povezane persistentne okužbe, bradavic na spolovilih, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu je bila 47,2 % (95-odstotni IZ: 33,5; 58,2).
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 88.7% (95% CI: 78.1, 94.8).
Učinkovitost cepiva Silgard proti kombinirani pojavnosti s HPV 6, HPV 11, HPV 16 ali HPV 18 povezane persistentne okužbe, bradavic na spolovilih, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu je bila 88,7 % (95-odstotni IZ: 78,1; 94,8).
The efficacy of Silgard in 16- through 26-year-old women was assessed in 4 placebo-controlled, double-blind, randomized Phase II and III clinical studies including a total of 20,541 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Učinkovitost cepiva Silgard pri ženskah, starih 16 do 26 let, je bila ovrednotena v 4-ih s placebom nadzorovanih, dvojno slepih, randomiziranih kliničnih študijah II. in III. faze, v katere je bilo vključenih skupno 20.541 žensk, ki so bile v študije vključene in cepljene brez predhodnega pregleda za prisotnost okužbe s HPV.
The efficacy of Silgard in 24- through 45-year-old women was assessed in 1 placebo-controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Učinkovitost cepiva Silgard pri ženskah, starih 24 do 45 let, je bila ovrednotena v 1 s placebom nadzorovani, dvojno slepi, randomizirani klinični študiji III. faze (Protokol 019, FUTURE III), v katero je bilo vključenih 3.817 žensk, ki so bile v študijo vključene in cepljene brez predhodnega pregleda za prisotnost okužbe s HPV.
The efficacy of simeprevir in combination with peginterferon alfa and ribavirin was evaluated in patients with HCV genotype 1 or 4 infection, with or without HIV-1 co-infection, who were treatment-naïve or treatment-experienced (following prior interferon-based therapy) (tables 17 and 18).
Učinkovitost simeprevirja v kombinaciji s peginterferonom alfa in ribavirinom so ocenjevali pri bolnikih z okužbo s HCV genotipa 1 ali 4, z ali brez sočasne okužbe s HIV-1, ki še niso bili zdravljeni ali pa so zdravljenje že prejemali (po predhodnem zdravljenju na osnovi interferona) (preglednici 17 in 18).
The efficacy of Simponi was demonstrated in three multi-centre, randomised, double-blind, placebo-controlled studies in over 1500 patients ≥ 18 years of age with moderately to severely active RA diagnosed according to American College of Rheumatology (ACR) criteria for at least 3 months prior to screening.
Varnost in učinkovitost zdravila Simponi so ocenili v multicentrični, randomizirani, dvojno slepi, s placebom nadzorovani študiji (GO-AHEAD) pri 197 odraslih bolnikih s hudim aktivnim nr-aksialnim SpA (opredeljenih kot tisti bolniki, ki so izpolnjevali razvrstitvena merila ASAS za aksialni spondiloartritis, vendar niso izpolnjevali modificiranih newyorških meril za AS).
The efficacy of STAYVEER has not been established in patients with severe pulmonary arterial hypertension.
Učinkovitost zdravila STAYVEER pri bolnikih s hudo pljučno arterijsko hipertenzijo ni bila ugotovljena.
The efficacy of Stribild in HIV-1 infected virologically-suppressed patients is based on the analyses of 48-week data from two randomised, open-label studies (Studies GS-US-236-0115 and GS-US-236-0121) and a single group open-label study (Study GS-US-236-0123) (n = 910; 628 receiving Stribild).
Učinkovitost zdravila Stribild pri bolnikih z virusno supresijo, okuženih s HIV-1, temelji na analizah podatkov za 48 tednov iz dveh randomiziranih, odprtih študij (študiji GS-US-236-0115 in GS-US-236-0121) in odprte študije z eno skupino (študija GS-US-236-0123) (n = 910; 628 jih je prejemalo zdravilo Stribild).
The efficacy of subcutaneous administered tocilizumab in alleviating the signs and symptoms of RA and radiographic response, was assessed in two randomised, double-blind, controlled, multi-center studies.
Učinkovitost subkutano danega tocilizumaba za ublažitev znakov in simptomov revmatoidnega artritisa in radiološki odziv so ocenili v dveh randomiziranih, dvojno slepih, kontroliranih multicentričnih študijah.
The efficacy of Tarceva in first-line treatment of patients with EGFR activating mutations in NSCLC was demonstrated in a phase III, randomized, open-label trial (ML20650, EURTAC).
Učinkovitost zdravila Tarceva v prvi liniji zdravljenja pri bolnikih z EGFR-aktivirajočimi mutacijami pri nedrobnoceličnem raku pljuč je bila dokazana v odprti, randomizirani študiji faze III (ML20650, EURTAC).
The efficacy of the BID (twice daily) regimen has been evaluated versus the TID (three times daily) regimen primarily in patients naïve to PIs (see section 5.1)
Učinkovitost odmerjanja dvakrat na dan v primerjavi z odmerjanjem trikrat na dan so proučevali v glavnem pri bolnikih, ki se še niso zdravili s PI (glejte poglavje 5.1).
The efficacy of the vaccine in the face of intermediate to high levels of maternally derived antibodies in piglets has been demonstrated.
Pujski: Dokazana je bila učinkovitost cepiva pri pujskih s srednjimi do visokimi vrednostmi maternalnih protiteles.
The efficacy of the vaccine was demonstrated in a number of laboratory trials in sheep and cattle of the minimum recommended age.
Učinkovitost cepiva je bila dokazana v številnih laboratorijskih preskušanjih pri ovcah in govedu od priporočene starosti dalje.
The efficacy of the veterinary medicinal product at the recommended dosage is not sufficient for the treatment of infections with Capillaria spp.
Učinkovitost zdravila za uporabo v veterinarski medicini v priporočenem odmerku ni zadostna za zdravljenje infestacij s Capillaria spp.
The efficacy of the veterinary medicinal product at the recommended dosage is not sufficient for the treatment of infections with Capillaria spp.
Učinkovitost zdravila za uporabo v veterinarski medicini v priporočenem odmerku ni zadostna za zdravljenje infestacij s Cappilaria spp.